Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763534 | 0.84 | BTK (0.41) | BTKMMP2MMP3PTGDR2 | |
| SCHEMBL1763732 | 0.84 | CYP2D6 (0.39) | BTKMMP2MMP3SLC9A1PTGDR2 | |
| SCHEMBL1764089 | 0.83 | SLC9A1 (0.46) | LMNAMMP2MMP3CYP3A4SLC9A1 | |
| SCHEMBL1763560 | 0.82 | SLC9A1 (0.55) | LMNACYP3A4SLC9A1 | |
| SCHEMBL1763596 | 0.77 | SLC9A1 (0.57) | P2RX7CYP3A4SLC9A1 | |
| SCHEMBL1764257 | 0.75 | SLC9A1 (0.47) | CYP3A4SLC9A1 | |
| SCHEMBL1763592 | 0.74 | SLC9A1 (0.49) | LMNAMMP2MMP3CYP3A4SLC9A1 | |
| SCHEMBL1763934 | 0.73 | SLC9A1 (0.54) | CYP3A4SLC9A1 | |
| SCHEMBL12593566 | 0.73 | NAMPT (0.38) | LMNAMMP2MMP3CYP3A4SLC9A1 | |
| SCHEMBL1763563 | 0.72 | SLC9A1 (0.51) | CYP3A4SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | P2RX7 906/4885LMNA 3754/4885BTK 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.